[go: up one dir, main page]

MX2022015799A - Composicion y metodo para el tratamiento del dolor cronico. - Google Patents

Composicion y metodo para el tratamiento del dolor cronico.

Info

Publication number
MX2022015799A
MX2022015799A MX2022015799A MX2022015799A MX2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A MX 2022015799 A MX2022015799 A MX 2022015799A
Authority
MX
Mexico
Prior art keywords
chronic pain
composition
treating chronic
relates
treating
Prior art date
Application number
MX2022015799A
Other languages
English (en)
Inventor
Richard Hopkins
Meghan Gail Thomas
Oludare Odumosu
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901947A external-priority patent/AU2020901947A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of MX2022015799A publication Critical patent/MX2022015799A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden ?9 -tetrahidrocannabinol (THC), cannabidiol (CBD) y cannabigerol (CBG) y un componente terpeno, y su uso en el tratamiento del dolor crónico. La invención también se refiere a métodos para tratar el dolor crónico, especialmente el dolor crónico en atletas.
MX2022015799A 2020-06-12 2021-06-11 Composicion y metodo para el tratamiento del dolor cronico. MX2022015799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901947A AU2020901947A0 (en) 2020-06-12 Composition and method for treating chronic pain
PCT/AU2021/050602 WO2021248207A1 (en) 2020-06-12 2021-06-11 Composition and method for treating chronic pain

Publications (1)

Publication Number Publication Date
MX2022015799A true MX2022015799A (es) 2023-04-11

Family

ID=78523907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015799A MX2022015799A (es) 2020-06-12 2021-06-11 Composicion y metodo para el tratamiento del dolor cronico.

Country Status (14)

Country Link
US (1) US20230218566A1 (es)
EP (1) EP4164628A4 (es)
JP (1) JP2023529476A (es)
KR (1) KR20230069080A (es)
CN (1) CN115843248A (es)
AU (1) AU2021215262B2 (es)
BR (1) BR112022025302A2 (es)
CA (1) CA3186718A1 (es)
CL (1) CL2022003507A1 (es)
CO (1) CO2023000130A2 (es)
IL (1) IL299008A (es)
MX (1) MX2022015799A (es)
PE (1) PE20230837A1 (es)
WO (1) WO2021248207A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
BR112019026877A2 (pt) 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser
US20250073252A1 (en) * 2021-08-03 2025-03-06 Pebble Global Holdings Non-psychoactive multi-cannabinoid and terpene-based therapeutic compositions and methods of their administration
WO2025140869A1 (en) * 2023-12-28 2025-07-03 Linnea Sa Process for stabilising a macerated oil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180130544A (ko) * 2016-03-28 2018-12-07 투 파마슈티컬스 엘엘씨 위장관의 염증성 질환의 치료용 칸나비노이드 및 칸나비스-계 조성물 및 방법
MX386086B (es) * 2016-08-03 2025-03-18 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis
US20180311180A1 (en) * 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
CA3076929A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
EP3704263A4 (en) * 2017-10-30 2021-08-25 Endocanna Health, Inc. GRAPHIC USER INTERFACES FOR DETERMINING CUSTOMIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use
ES2973731T3 (es) * 2018-04-09 2024-06-24 Portland Tech Holdings Llc Extracto de cáñamo para el tratamiento del dolor en animales
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
EP3876918A4 (en) * 2018-11-09 2022-08-10 Cronos Group Inc. LIQUID COMPOSITION FOR AN ELECTRONIC VAPOR DEVICE
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods

Also Published As

Publication number Publication date
CL2022003507A1 (es) 2023-06-09
KR20230069080A (ko) 2023-05-18
CN115843248A (zh) 2023-03-24
CO2023000130A2 (es) 2023-05-19
PE20230837A1 (es) 2023-05-19
WO2021248207A1 (en) 2021-12-16
US20230218566A1 (en) 2023-07-13
AU2021215262A1 (en) 2021-11-04
CA3186718A1 (en) 2021-12-16
IL299008A (en) 2023-02-01
JP2023529476A (ja) 2023-07-10
AU2021215262B2 (en) 2023-12-14
BR112022025302A2 (pt) 2023-02-28
EP4164628A1 (en) 2023-04-19
EP4164628A4 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
MX2022015799A (es) Composicion y metodo para el tratamiento del dolor cronico.
Shara et al. Efficacy and safety of white willow bark (Salix alba) extracts
Farid et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis
EP4640275A3 (en) USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY
SA521421897B1 (ar) تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
NZ729290A (en) Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
CO6382172A2 (es) Efectos antitumorales de combinaciones cannabinoides
ZA202110111B (en) Methods and compositions for treating liver disorders
ECSP055706A (es) Composición que comprende extractos de panax ginseng y paullinia cupana
BRPI0511322A (pt) composições adequadas para o tratamento de sinais cutáneos provenientes do envelhecimento, tablete e formulação de tablete
WO2008094825A3 (en) Compositions and methods for maintaining, strengthening, improving or promoting eye health
ATE361746T1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
Xia et al. Role of oxidative stress in the concurrent development of osteoporosis and tendinopathy: emerging challenges and prospects for treatment modalities
MX2018002533A (es) Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
PH12017502145A1 (en) Composition and uses thereof
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
GB2415905A (en) Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids
TW200724150A (en) Plant extracts for treating skin disorders and enhancing healing of wounds for diabetics patients